Technology

Bioelectronic Medicine for Inflammatory Diseases

SetPoint is developing breakthrough therapies to reduce systemic inflammation by delivering digital doses of electricity to the vagus nerve using an implantable bioelectronic device. This activates the body’s natural Inflammatory Reflex and is intended to dampen inflammation to improve clinical signs and symptoms associated with rheumatoid arthritis (RA) and Crohn’s disease.

First-in-Human Pilot Study Validates Bioelectronic Approach

SetPoint Medical first announced positive results from the first-ever human study using an implanted bioelectronic medicine device to treat rheumatoid arthritis at the American College of Rheumatology Annual Meeting in November 2012.

The results of this open-label pilot study confirm extensive preclinical studies and suggest efficacy with bioelectronic medicines. The results are similar to those typically achieved with drugs currently used to treat RA. At the primary end point, using the Disease Activity Score (DAS) and the American College of Rheumatology Response Rate (ACR), both standard RA efficacy measures for RA, twelve of seventeen patients demonstrated clinically significant improvements and several reached remission.

A comprehensive analysis of the results of this study can be found in the Proceedings of the National Academy of Sciences.

The SetPoint Platform

SetPoint’s proprietary bioelectronic platform consists of an implantable microregulator, wireless charger and iPad prescription pad application.

SetPoint is using its bioelectronic platform to develop safe and effective alternative therapies to target other diseases.

Benefits of Bioelectronic Therapy

SetPoint intends to offer patients and providers a better alternative for the treatment of chronic inflammatory diseases with less risk and lower cost than drug therapy. SetPoint believes bioelectronic therapy for the treatment of rheumatoid arthritis and other inflammatory diseases will be ground-breaking for patients, physicians and payors:

The SetPoint Platform

  • For patients, the implanted system is intended to last 10 years, freeing them from routine injections or pills and the risks and substantial cost associated with current biologic treatments.
  • For physicians, the device is designed to provide a novel and less expensive alternative for patients suffering from RA and Crohn’s disease.
  • For payors, the device may improve the lives of those suffering from RA and Crohn’s disease, while decreasing costs by half or more.